Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically ...
The full Prescribing Information for YERVOY includes a boxed warning for immune-mediated adverse reactions. YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell ...
More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy. The combination use of Opdivo ...
Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone Forty-Seven Percent of Patients Treated with ...
PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced that the European Commission has approved YERVOY TM (ipilimumab) for the treatment of adult patients with previously-treated ...
Bristol Myers Squibb today announced that more than half of advanced renal cell carcinoma patients treated with the Opdivo ® plus Yervoy ® combination were alive after four years across the entire ...
An additional analysis showed similar results with a significant benefit seen for Opdivo plus low-dose Yervoy relative to sunitinib on change from baseline at a pre-planned 25-week landmark. Assessed ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival ...
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results